Parkman Healthcare Partners LLC Increases Stock Holdings in Becton, Dickinson and Company $BDX

Key Points

• Parkman Healthcare Partners LLC significantly increased its stake in Becton, Dickinson and Company by 70.8%, becoming its 6th largest holding with a total investment of approximately $27.55 million.
• Becton, Dickinson and Company reported a 10.4% year-over-year revenue increase in its latest quarterly earnings, with an EPS of $3.68, surpassing analysts' estimates.
• The company announced a quarterly dividend of $1.04, reflecting an annualized dividend yield of 2.2%, with future guidance set at 14.300-14.450 EPS for FY 2025.

Parkman Healthcare Partners LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 70.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 120,283 shares of the medical instruments supplier's stock after acquiring an additional 49,879 shares during the quarter. Becton, Dickinson and Company makes up about 3.3% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 6th largest position. Parkman Healthcare Partners LLC's holdings in Becton, Dickinson and Company were worth $27,552,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Northcape Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 0.5% during the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after acquiring an additional 51 shares during the last quarter. Alpha Omega Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 5.7% during the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after buying an additional 53 shares during the last quarter. Brady Family Wealth LLC raised its stake in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after buying an additional 53 shares during the last quarter. Diversified Trust Co raised its stake in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after buying an additional 53 shares during the last quarter. Finally, REAP Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 55 shares during the period. Institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the sale, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. The trade was a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Piper Sandler restated a "neutral" rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $211.44.

Becton, Dickinson and Company Stock Down 0.5%

Shares of BDX traded down $1.02 on Tuesday, hitting $190.56. The company's stock had a trading volume of 1,289,931 shares, compared to its average volume of 1,906,717. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm's fifty day moving average price is $185.72 and its 200-day moving average price is $192.33. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The firm has a market capitalization of $54.62 billion, a price-to-earnings ratio of 34.27, a P/E/G ratio of 1.43 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.